A couple of ARK Invest funds run by ETF star Cathie Wood made a huge buy on Wednesday. Specifically, these exchange-traded funds bought roughly $65 million worth of CRISPR Therapeutics AG (NASDAQ: CRSP), as the prices of these funds were fairly positive on Wednesday. Note that their performance is mixed in the past year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 150,210 shares of CRISPR, and ARK Innovation ETF (NYSEARCA: ARKK) bought 527,747 shares. At Wednesday’s closing prices, this would have valued the sales at roughly $65.6 million altogether. Even though this is a small fraction of their total holdings, every little bit counts. The innovation ETF is up about 10% and the other is down 1% in the past year.
|ARKG||Buy||DYNS||DYNAMICS SPECIAL PURPOSE||577|
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St., owner of 247wallst.com.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.